Typhoid fever

Lancet. 2015 Mar 21;385(9973):1136-45. doi: 10.1016/S0140-6736(13)62708-7. Epub 2014 Oct 21.

Abstract

Control of typhoid fever relies on clinical information, diagnosis, and an understanding for the epidemiology of the disease. Despite the breadth of work done so far, much is not known about the biology of this human-adapted bacterial pathogen and the complexity of the disease in endemic areas, especially those in Africa. The main barriers to control are vaccines that are not immunogenic in very young children and the development of multidrug resistance, which threatens efficacy of antimicrobial chemotherapy. Clinicians, microbiologists, and epidemiologists worldwide need to be familiar with shifting trends in enteric fever. This knowledge is crucial, both to control the disease and to manage cases. Additionally, salmonella serovars that cause human infection can change over time and location. In areas of Asia, multidrug-resistant Salmonella enterica serovar Typhi (S Typhi) has been the main cause of enteric fever, but now S Typhi is being displaced by infections with drug-resistant S enterica serovar Paratyphi A. New conjugate vaccines are imminent and new treatments have been promised, but the engagement of local medical and public health institutions in endemic areas is needed to allow surveillance and to implement control measures.

Publication types

  • Review

MeSH terms

  • Africa
  • Anti-Bacterial Agents / therapeutic use*
  • Asia
  • Drug Resistance, Bacterial / physiology
  • Drug Resistance, Multiple
  • Humans
  • Paratyphoid Fever / drug therapy
  • Paratyphoid Fever / prevention & control*
  • Salmonella enterica / immunology
  • Salmonella enterica / physiology
  • Salmonella paratyphi A / immunology
  • Salmonella paratyphi A / physiology*
  • Typhoid Fever / drug therapy
  • Typhoid Fever / prevention & control*
  • Typhoid-Paratyphoid Vaccines / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Typhoid-Paratyphoid Vaccines